Answers are grounded in this paper and cite their sources.
TP53 is one of the most constantly mutated suppressor genes in breast cancer and has been associated with aggressive biological behavior as well as poor clinical outcome. Still, its prognostic value specifically among mastectomy-treated cases remains partly understood. This study aimed to estimate the role of TP53 gene mutation in assessing long-term survival following mastectomy in breast cancer cases. In this retrospective cohort study, 873 breast cancer cases who underwent mastectomy between 2010 and 2018 were analyzed. TP53 mutation analysis was primarily performed by PCR amplification and Sanger sequencing of exons 5–8, with NGS used for validation in a subset of cases. Clinical, pathological, and treatment variables were collected. Long-term outcome, including disease-free survival (DFS) and overall survival (OS), were estimated using Kaplan–Meier analysis and Cox Proportional hazards models. TP53 mutation was identified in 25.3% of patients (n = 221). Compared with TP53 wild-type tumors, TP53-mutated cancers were significantly associated with higher tumor grade, lymphovascular invasion, and hormone receptor–negative phenotype (p < 0.001). Kaplan–Meier analysis demonstrated poorer survival among TP53-mutated patients than among TP53 wild-type patients. At approximately 60 months, DFS was about 29% versus 58%, respectively, and OS was about 36% versus 65%, respectively; at approximately 120 months, DFS was about 12% versus 31%, and OS was about 21% versus 37% (log-rank p < 0.001). In multivariable Cox analysis, TP53 mutation remained an independent predictor of poor DFS (HR: 2.14, 95% CI: 1.68–2.73) and OS (HR: 2.32, 95% CI: 1.75–3.08). TP53 gene mutation is a strong independent predictor of poor long-term outcome among breast cancer cases undergoing mastectomy. These findings emphasize the significance of incorporating TP53 mutation profiling into post-mastectomy risk stratification and punctuate the need for farther exploration on targeted remedial strategies for TP53-mutated breast cancer. 1) TP53 mutations were identified in 25.3% of mastectomy-treated breast cancers. 2) TP53-mutated tumors were associated with aggressive clinicopathological features. 3) TP53 mutation was associated with lower disease-free and overall survival at approximately 60 and 120 months. 4) TP53 mutation independently predicted poorer DFS and OS after mastectomy. 5) TP53 profiling may improve post-mastectomy risk stratification and management.
No takes yet. Share an insight, caveat, or question.
Gökçe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: